Eli Lilly and Boehringer Ingelheim have rolled back large-scale investments in Germany in response to proposed health spending cuts. According to Handelsblatt reporting carried in the provided materials, Boehringer dropped a €900 million plan and Lilly is halving a €2.3 billion injectable GLP-1 manufacturing investment, while still aiming to open the facility in 2027 but at half capacity. The companies’ statements point to uncertainty from the German government’s draft law intended to save more than €16 billion and address state insurer deficits, including changes that could increase prescription costs for insured patients. For biotech and pharma stakeholders, the dispute highlights the operational risk of policy-driven demand and capacity planning across Europe—particularly for supply-constrained product categories such as GLP-1 medicines.